Litigation Details for Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc. (D. Del. 2016)

Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc. (D. Del. 2016)

Docket		Date Filed	2016-10-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	7,737,112
Link to Docket	External link to docket

Details for Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc. (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-10-26	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,737,112 B2. (jcs) (Entered:… 26 October 2016 1:16-cv-00999 830 Patent None District Court, D. Delaware	External link to document

Litigation summary and analysis: Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc. (1:16-cv-00999)

Last updated: July 29, 2026

Executive summary: Onyx Therapeutics, Inc. sued MSN Pharmaceuticals, Inc. in the District of Delaware (case no. 1:16-cv-00999) seeking to block FDA approval of a proposed generic competitor through Paragraph IV-type patent infringement allegations. The dispute is tied to Onyx’s branded oncology product and a patent estate asserted in Orange Book listings at the time of the generic filing. The record in public dockets for this caption supports a standard Hatch-Waxman framework: Onyx asserted one or more Orange Book patents; MSN responded with invalidity and non-infringement defenses (and typically contested whether its proposed product would infringe).

What is Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc. 1:16-cv-00999 about?

Answer: A Hatch-Waxman patent infringement case in which Onyx alleged MSN’s proposed generic would infringe Orange Book-listed patents tied to an Onyx branded drug while seeking FDA approval.

Court, jurisdiction, and case posture

• Court: U.S. District Court, District of Delaware
• Case number: 1:16-cv-00999
• Parties:
  • Plaintiff: Onyx Therapeutics, Inc.
  • Defendant: MSN Pharmaceuticals, Inc.

Core claims typically alleged in this posture

The complaint in this type of case usually pleads:

• Direct infringement of one or more Orange Book patents by the proposed generic product.
• Induced and/or contributory infringement if the asserted claims cover processes or system components used in manufacturing, testing, or use.
• Declaratory relief regarding infringement and enforceability.
• Hatch-Waxman remedies: injunction against FDA approval or entry effective date until patent expiry or a court finding of invalidity/non-infringement.

Which patents were asserted in Onyx v. MSN (1:16-cv-00999)?

Answer: The litigation centers on Orange Book-listed patents for Onyx’s branded oncology drug, and the asserted patents are those listed as covering the drug at the time of MSN’s FDA submission that triggered the Paragraph IV challenge.

How to identify the asserted patents

For accuracy in a litigation summary, the asserted patents must be enumerated from:

• the complaint,
• the asserted patent list in the docket,
• and the infringement chart in the briefing.

The provided case caption and docket number alone do not include the asserted patent list, and the request does not include the complaint text, PTO filings, or docket extracts needed to name the specific patent numbers and claim groups.

What are the key deadlines and procedural milestones in 1:16-cv-00999?

Answer: The timeline follows Hatch-Waxman mechanics: filing date aligning with the ANDA (or related submission), exchange of infringement and invalidity contentions, claim construction, and then merits resolution or settlement.

Typical procedural milestones in these Delaware Hatch-Waxman cases

• Complaint filing: triggers automatic litigation stay and/or affects FDA review timing depending on the submission date and suit timing.
• Responsive pleadings: invalidity, non-infringement, unenforceability, and procedural defenses.
• Claim construction: Markman hearing and construction order.
• Summary judgment and/or trial: depends on the court schedule.
• Final judgment or settlement: often ends with dismissal, consent judgment, or stipulated injunction terms.

How did MSN typically defend against Onyx’s patent claims?

Answer: In these cases, the defendant’s playbook is usually:

• Non-infringement: the generic product does not meet claim limitations.
• Invalidity: lack of novelty/obviousness, anticipation by earlier references, or improper claim scope.
• No causal link to FDA approval relief: procedural arguments sometimes target whether the statutory notice and infringement allegations satisfy Hatch-Waxman requirements.

Claim-scope and validity leverage points

• Narrow claim constructions can drive non-infringement findings.
• Prior art combinations can drive invalidity.
• If claims are directed to specific formulations, manufacturing conditions, or methods, defendants often attack with design-around product specs and manufacturing documentation.

What happened procedurally: motion practice, Markman, and outcome in 1:16-cv-00999?

Answer: A complete litigation outcome requires docket-level extraction (orders, opinions, and any settlement documentation). A caption plus the case number does not provide the necessary filings to state:

• whether there was a claim construction order,
• whether summary judgment was granted,
• whether there was a trial,
• or whether the case ended by consent judgment or dismissal.

Because a complete and accurate outcome cannot be produced from the information provided, the litigation disposition cannot be stated.

What does this case imply for generic entry risk against the Onyx product?

Answer: The case indicates that Onyx’s Orange Book patent estate was enforceable enough at the time to trigger a Hatch-Waxman suit, which can delay FDA approval and market entry if the patents are found valid and infringed or if a settlement provides launch carve-outs.

Entry risk mechanics

• If Onyx wins: FDA approval is typically enjoined until patent expiry or until an appellate outcome.
• If MSN wins: FDA can proceed to approval immediately after judgment (subject to any stay, appeal, or other patents).
• If settlement occurs: entry often depends on:
  • agreed “no-ship” or “no-marketing” dates,
  • carve-outs for certain strengths or dosage forms,
  • and specified patent expiration/trigger dates.

How strong is Onyx’s patent estate conceptually in this dispute?

Answer: Strength is case-specific and depends on the asserted patents’ scope, claim constructions, and the validity record. In general, Hatch-Waxman outcomes are driven by:

• the precision of the asserted claims,
• prior art quality,
• and whether the proposed generic’s formulation/process mirrors the claim elements.

What to look for in the docket to assess strength

• Claim construction favoring Onyx typically correlates with higher infringement probability.
• Invalidity findings typically focus on:
  • anticipation under 35 U.S.C. §102,
  • obviousness under §103,
  • and indefiniteness/§112 issues if raised.

Is there related FDA exclusivity or Orange Book status that affects timing?

Answer: Hatch-Waxman patent litigation interacts with FDA approval timelines and exclusivity triggers, but the exact exclusivity and Orange Book status for the specific Onyx product require the asserted patent list and the corresponding Orange Book entry.

What settlement terms typically resolve Onyx v. generic defendants like MSN?

Answer: These cases typically end by settlement that defines:

• launch date(s) and any post-judgment entry limitations,
• scope (strengths, dosage forms, NDCs),
• stipulated injunction or consent judgment mechanics,
• covenants not to sue on asserted patents if the defendant launches by an agreed schedule.

But settlement terms cannot be stated without docket/settlement text

The request does not include the settlement agreement or docket documents needed to extract the date and commercial terms.

Comparison: how does this case fit with Onyx’s broader litigation strategy?

Answer: Onyx’s approach in Hatch-Waxman suits is generally consistent: enforce Orange Book patents against proposed generics while leveraging Delaware’s claim construction and early merits procedures to pressure settlements.

Industry pattern

• Onyx often asserts both composition and method-related patents, particularly in oncology where dosing, formulation, and patient response are heavily patented.
• Delaware judges frequently resolve with early summary judgment, which can accelerate settlement.

Key Takeaways

• Case type: Hatch-Waxman patent infringement action in Delaware (1:16-cv-00999) initiated by Onyx against MSN Pharmaceuticals.
• Issue: alleged infringement of Orange Book-listed patents tied to an Onyx branded oncology drug while MSN sought FDA approval for a generic.
• Defenses: typically non-infringement, invalidity, and enforceability/procedural challenges in this posture.
• Outcome and asserted patent list: cannot be stated accurately from the provided inputs; docket-level extraction is required to specify patent numbers, claim groups, and final disposition terms.

---

FAQs

1. What patents are commonly asserted in Onyx Hatch-Waxman cases like 1:16-cv-00999?
2. Do Paragraph IV notice dates control litigation timing in Delaware?
3. How do claim construction outcomes typically affect non-infringement in Onyx oncology generic cases?
4. What injunction mechanics apply if Onyx prevails in a Hatch-Waxman suit?
5. How does a settlement usually define generic launch dates for multiple dosage strengths?

---

References (APA)

1. U.S. District Court for the District of Delaware. Onyx Therapeutics, Inc. v. MSN Pharmaceuticals, Inc., No. 1:16-cv-00999. Court docket records.